Trials / Enrolling By Invitation
Enrolling By InvitationNCT06112327
Long-term Follow-up of Participants Dosed With an Investigational Gene Editing Therapy for Cardiovascular Disease
Long-term Follow-up Study of Investigational Gene-editing Therapies in Participants With or at High Risk for Cardiovascular Disease
- Status
- Enrolling By Invitation
- Phase
- —
- Study type
- Observational
- Enrollment
- 116 (estimated)
- Sponsor
- Verve Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
LTF-001 is a long-term follow-up study of participants who received an investigational gene-editing therapy developed by the sponsor to evaluate the long-term effects of the investigational therapy. Participants will be followed for a total of 15 years after the first administration of the gene-editing therapy.
Conditions
- Atherosclerotic Cardiovascular Disease
- Heterozygous Familial Hypercholesterolemia
- Hypercholesterolemia
Timeline
- Start date
- 2024-06-09
- Primary completion
- 2039-10-01
- Completion
- 2039-10-01
- First posted
- 2023-11-01
- Last updated
- 2026-04-08
Locations
3 sites across 2 countries: New Zealand, United Kingdom
Source: ClinicalTrials.gov record NCT06112327. Inclusion in this directory is not an endorsement.